

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
NOVEMBER 18, 2014

CALL TO ORDER / ANNOUNCEMENTS

The NCI at Frederick Institutional Biosafety Committee was convened at 12:10 pm in Building 549 Executive Board Room with the following members in attendance:

Voting (Quorum = 8)

Katalin Baranji
 Michael Baseler (*regrets*)
 Theresa Bell
 Rev. David Betzner
 Stephen Creekmore
 Bruce Crise
 Eric Freed
 Melinda Hollingshead

Stephen Hughes
 Sarah Hooper (*regrets*)
 Serguei Kozlov (*regrets*)
 Dan McVicar
 Raja Sriperumbudur
 Lucien Winegar
 Sharon Altmann

Non-Voting

Walter Hubert (*regrets*)
 Karen Barber
 Matthew Nawn

APPROVAL OF MINUTES FROM THE OCTOBER 21 MEETING

The minutes from the October 21, 2014 meeting were approved. A motion and second were made. (For: 12; Against: 0; Abstain: 0)

ACCIDENT REVIEWS : Three accidents: all sharps with no biological exposure

1. Cleaning of scalpel blades
2. Needle sticks (2) with chemical compounds only.

REVIEW OF PROTOCOLS

NEW REGISTRATIONS

- ❖ Matthew Holderfield – 14-40 – RAS screening assay development and biological characterization – This lab is interested in KRAS driven cancers and are currently developing cellular and biochemical assays that will be used for high throughput screening to identify compounds that prevent or disrupt protein-protein interactions involving KRAS. The focus is to understand the nature of KRAS-CRAF and KRAS-Calmodulin binding and mechanisms of KRAS dependent proliferation. The committee needs more information and clarifications. A motion to defer to full committee in

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
NOVEMBER 18, 2014

December was made by Sharon Altmann and seconded by Rev. Betzner. (For: 12; Against: 0; Abstain: 0)

- ❖ Michael Dean – 14-41 – Molecular Genetics Studies-Human Genetics Section – This lab carries out the culture of human cell lines, transfection of protein expression vectors containing human genes, receipt and storage of human blood samples, and human saliva samples. Extraction of DNA from human tissue samples and saliva samples. A motion was made to approve pending clarifications by Eric Freed and seconded by Raja Sriperumbudur. (For: 12; Against: 0; Abstain: 0)
- ❖ Ligia Pinto – 14-42 – Storage of cell lines only – This lab is storing human and mouse cell lines in the vapor phase of a LN2 storage container in a locked room with limited access. These cell lines will remain in storage until an applicable project requires their use and at which time an amendment will be created describing the cell lines use and handling. A motion was made to approve by Katalin Baranji and seconded by Raja Sriperumbudur. (For: 12; Against: 0; Abstain: 0)
- ❖ Stuart LeGrice – 14-43 – Reverse Transcriptase Biochemistry – This project focuses on mutagenesis followed by functional analyses of retroviral, hepanaviral and retrotranspon reverse transcriptases. Mutagenesis and protein expression will be performed in E.coli. Subsequently, the proteins will be tested with functional assays utilizing fluorescently labeled nucleic acids. These assays may also include synthetic or natural small molecules. A motion was made to approve pending clarifications by Steve Hughes and seconded by Steve Creekmore. (For: 12; Against: 0; Abstain: 0)

❖ **RENEWAL REGISTRATIONS**

OUTSTANDING ITEMS

- ❖ James McMahan – 14-24 (P191187JMA) – Whole Cell Anti-HIV Screening Assay. The general assay involves the infection of CEM-SS cells with HIV-1 in the presence of the test compound. A sub-assay involves the infection of H9 cells with HIV-1. This is necessary to resupply our virus stock used in the anti-HIV whole-cell assay. A motion was made to approve pending clarifications by Eric Freed and seconded by Theresa Bell. (For: 12; Against: 0; Abstain: 0)
- ❖ Peter Gorelick – 14-26 (08-27). Serological diagnostic testing of non-human primates for the presence of potentially adventitious viruses - Diagnostic serological testing for routine health monitoring of NHPs. (Bell) Deferred to full committee in August. Awaiting additional documentation.
- ❖ Stephen Lockett – 14-22 (08-46) – Ras project 3 and CCR support. Discovery methods to directly target oncogenic Ras protein, and live and fixed cell fluorescence labeling in support of CCR research. (Zudaire/Hughes/Altmann) Deferred to full committee in August. Awaiting additional documentation. **ON HOLD. WAITING ON CHANGES IN THE DEPARTMENT BEFORE SUBMITTING. As of October 14, 2014, no updates have been made.**

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
NOVEMBER 18, 2014

- ❖ Dimiter Dimitrov 13-38 (04-04, 08-20): Developing anti-viral vaccines and human antibodies against infectious diseases and cancer antigens by using recombinant membrane proteins of HIV, Nipah, Hendra, Dengue viruses and cancer antigens. Committee requested additional clarifications and a Vaccinia-specific SOP as well as a lab visit. Post-meeting, Theresa Bell learned that the lab was relocating and suggested that the space that will be used for the Vaccinia work should not be evaluated until the move has been completed. No Vaccinia work is being performed at this time. **Continue deferral until lab move and observation is completed.** For: 8; Against: 0; Abstain: 0

AMENDMENTS

Twenty four amendments were processed and approved between August and September IBC meetings.

OTHER BUSINESS

ADJOURNMENT

The meeting adjourned at 1:45 pm.

Next meetings:

December 16, 2014

January 20, 2015